top of page
Search


Lipid Nanoparticle News and Research Summary (July 29 - August 18, 2025)
Max-Planck-Institut für Kohlenforschung: New study reveals stereochemistry of lipid nanoparticles critically influences safety and efficacy in mRNA delivery
Nagoya University: Japanese researchers engineered a new lipid nanoparticle that delivers mRNA to cells five times more effectively using cyclic disulfide modifications
University of Pennsylvania: Study unlocks safer RNA therapies by reducing harmful inflammation caused by lipid nanoparticles using biodegradable lipids
7 days ago


Engineering circular guide RNA and CRISPR-Cas13d-encoding mRNA for the RNA editing of Adar1 in triple-negative breast cancer immunotherapy
This research falls under the broader scientific discipline of molecular biology and cancer therapeutics, specifically within RNA-guided genome editing and precision oncology. CRISPR-Cas13d systems represent a powerful class of RNA-targeting tools that can precisely edit target transcripts with minimal off-target effects. However, their clinical development faces significant challenges. One of these is the limited biostability of conventional linear guide RNAs (lgRNAs) suscep
Aug 4


Lipid Nanoparticle Research News: July 1-28, 2025
Nagoya University: New cyclic disulfide lipids deliver mRNA five times more effectively for cancer treatment
University of Ottawa: Development of nano-sized delivery agents with therapeutic potential beyond messenger function
University of Pennsylvania: Chemical modification of ionizable lipids reduces inflammation and boosts mRNA therapeutic effectiveness
Academic Journals: Multiple publications on circular guide RNA engineering, CRISPR-Cas13d systems, and advanced LNP ch
Jul 29


Technical Review: Local Delivery of IL-12 mRNA and Indoximod Prodrug for Enhanced Cancer Immunotherapy
This research falls within the rapidly evolving field of cancer immunotherapy and nanomedicine, specifically focusing on cytokine-based therapeutic approaches. The study addresses a critical challenge in IL-12 cytokine therapy - the immunosuppressive feedback mechanisms that limit its therapeutic efficacy1. IL-12 has demonstrated potent antitumor activity in preclinical models by promoting T helper type 1 (TH1) differentiation and enhancing cytotoxic T lymphocyte activity. Ho
Jul 14


PreciGenome at CRS 2025 Annual Meeting & Exposition
We’re excited to announce that PreciGenome will be exhibiting at the CRS 2025 Annual Meeting & Exposition! Join us at booth #406 to discover our latest innovations in lipid nanoparticle (LNP) technology. What we offer:
Advanced LNP synthesis instruments for efficient and reproducible nanoparticle production
High-quality LNP reagents to support your research and development
Comprehensive CRO services tailored for your LNP and drug delivery projects
Connect with our
Jul 8


Mayo Clinic RNA Research Facility poster featuring PreciGenome NanoGenerator for RNA research
We're proud to share that the Mayo Clinic Florida’s new RNA Research Facility has chosen the PreciGenome NanoGenerator™ Flex-S as their...
Jun 2
bottom of page